BioPharmSignal logoBioPharmSignal

Biotech News

AN2 Therapeutics to Present Phase 2 Design for Epetraborole in Polycythemia Vera at the 18th International Congress on Myeloproliferative Neoplasms

AN2 Therapeutics (ANTX)AN2 TherapeuticsClinical readout

MENLO PARK, Calif. --(BUSINESS WIRE)--Oct. 21, 2026-- AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics derived from its boron chemistry platform, today announced the presentation of a

Related news

ANTXAN2 Therapeutics2026-06-04 11:00 EST

AN2 Therapeutics Reports Positive Enabling Data Supporting Advancement of Oral AN2-502998 to Phase 2 Study for Chronic Chagas Disease

ANTXAN2 Therapeutics2026-08-31 22:00 EST

AN2 Therapeutics Presents Clinical and Translational Data Supporting Development of Epetraborole for Polycythemia Vera at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting

ASMBAssembly Biosciences2026-05-13 06:00 EST

Assembly Biosciences to Present Topline Phase 1a Data on Hepatitis Delta Virus Entry Inhibitor ABI-6250 at the EASL Congress 2026

SPROSpero Therapeutics2026-07-14 11:00 EST

Spero Therapeutics and Innovent Biologics Announce Exclusive License for SP001 (IBI355), a Phase 2-Ready Third-Generation Anti-CD40L Antibody

SPROSpero Therapeutics2026-07-27 13:00 EST

Spero Therapeutics Appoints Debra Jeske Zack, M.D., Ph.D., as Chief Medical Officer

IMNNImunon2026-06-22 20:15 EST

IMUNON to Present at the Life Sciences Investor Forum on June 25th

SCYXSCYNEXIS2026-10-22 12:00 EST

SCYNEXIS Completes Phase 1 Study of Intravenous SCY-247, a Novel, Triterpenoid Antifungal in Development for Treatment and Prevention of Invasive Fungal Diseases

AVIRAtea2026-07-14 11:00 EST

Atea Pharmaceuticals Initiates First-in-Human Phase 1 Clinical Trial of AT-587 for the Treatment of Hepatitis E Virus

ENTAEnanta Pharmaceuticals2026-06-18 11:00 EST

Enanta Pharmaceuticals Announces Advancement of its Zelicapavir Clinical Development Program for the Treatment of Respiratory Syncytial Virus (RSV)

OGENOragenics2026-05-05 12:30 EST

Oragenics Activates Second Site in Phase IIa Clinical Trial of ONP-002 for Concussion and Mild Traumatic Brain Injury.

View all latest news

AN2 Therapeutics

Boron-Based Drug Development AN2 Therapeutics develops small-molecule medicines derived from its boron chemistry expertise, with programs spanning hematology, infectious disease, and oncology. Epetraborole in Polycythemia Vera AN2 is preparing the EBO-PV-201 Phase 2 proof-of-concept study of epetraborole in phlebotomy-dependent...

Recent company news

ANTXAN2 Therapeutics2026-10-23 21:00 EST

AN2 Therapeutics, Inc. Reports Inducement Grants Under Listing Rule 5635(c)(4)

ANTXAN2 Therapeutics2026-10-21 11:00 EST

AN2 Therapeutics to Present Phase 2 Design for Epetraborole in Polycythemia Vera at the 18th International Congress on Myeloproliferative Neoplasms

ANTXAN2 Therapeutics2026-10-20 20:13 EST

AN2 Therapeutics to Participate at Upcoming Investor Conferences

ANTXAN2 Therapeutics2026-09-28 11:00 EST

AN2 Therapeutics Announces Extension of Funding for Tuberculosis Research Collaboration with GSK

ANTXAN2 Therapeutics2026-09-16 21:33 EST

AN2 Therapeutics, Inc. Reports Inducement Grants under Listing Rule 5635(c)(4)

Stock data

Close
3.64 USD
Market cap
146.59M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States